Investigational Agents Affecting Atherogenic Lipoproteins

Clinical Lipidology: A Companion to Braunwald's Heart Disease

Volumn , Issue , 2009, Pages 530-543

  Bays, Harold ^a  

^a LOUISVILLE METABOLIC AND ATHEROSCLEROSIS RESEARCH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 73849146917     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-141605469-6.50048-2     Document Type: Chapter

References (51)

1. Bays H, Stein EA Pharmacotherapy for dyslipidaemia-current therapies and future agents. Expert Opin Pharmacother 2003, 4:1901-1938.
2. Charlton-Menys V, Durrington PN Squalene synthase inhibitors: clinical pharmacology and cholesterol-lowering potential. Drugs 2007, 67:11-16.
3. Amano Y, Nishimoto T, Tozawa R Lipid-lowering effects of Tak-475, a squalene synthase inhibitor, in animal models of familial hypercholesterolemia. Eur J Pharmacol 2003, 466:155-161.
4. Menys VC, Durrington PN Squalene synthase inhibitors. Br J Pharmacol 2003, 139:881-882.
5. Manoukian AA, Bhagavan NV, Hayashi T Rhabdomyolysis secondary to lovastatin therapy. Clin Chem 1990, 36:2145-2147.
6. Wortmann RL Dose-related statin myopathy: is it an issue?. Cleve Clin J Med 2005, 72:751-756.
7. Nawarskas JJ HMG-COA reductase inhibitors and coenzyme Q10. Cardiol Rev 2005, 13:76-79.
8. Caso G, Kelly P, Mcnurlan MA Effect of coenzyme Q10 on myopathic symptoms in patients treated with statins. Am J Cardiol 2007, 99:1409-1412.
9. Thompson PD, Clarkson P, Karas RH Statin-associated myopathy. JAMA 2003, 289:1681-1690.
10. Bostedor RG, Karkas JD, Arison BH Farnesol-derived dicarboxylic acids in the urine of animals treated with zaragozic acid A or with farnesol. J Biol Chem 1997, 272:9197-9203.
11. Nishimoto T, Amano Y, Tozawa R Lipid-lowering properties of Tak-475, a squalene synthase inhibitor. in vivo and in vitro. Br J Pharmacol 2003, 139:911-918.
12. Bays HE, Weiss RJ, Rhyne JM, Chen Y, Lopez C, Spezzi AH, Lapaquistat acetate monotherapy: effects of a novel squalene synthase inhibitor on LDL cholesterol Levels and other lipid parameters in patients with primary hypercholesterolemia. Presented at American Heart Association conference, November 4-7, 2007 Orlando, FL, (abstract 682).
13. Forman BM, Ruan B, Chen J The orphan nuclear receptor Lxralpha is positively and negatively regulated by distinct products of mevalonate metabolism. Proc Natl Acad Sci U S A 1997, 94:10588-10593.
14. Bays HE, RB Goldberg The forgotton Bile Acid Sequestrants: Is Now a Good Time to Remember?. American Journal of Therapeutics 2007, 14:567-580.
15. Nishimoto T, Tozawa R, Amano Y Comparing myotoxic effects of squalene synthase inhibitor, T-91485, and 3-hydroxy-3-methylglutaryl coenzyme a (HMG-COA) reductase inhibitors in human myocytes. Biochem Pharmacol 2003, 66:2133-2139.
16. Bays H Statin safety: an overview and assessment of the data-2005. Am J Cardiol 2006, 97:6-26.
17. Ballantyne CM, Corsini A, Davidson MH Risk for myopathy with statin therapy in high-risk patients. Arch Intern Med 2003, 163:553-564.
18. Pasternak RC, Smith SC, Bairey-Merz CN ACC/AHA/NHLBI clinical advisory on the use and safety of statins. Circulation 2002, 106:1024-1028.
19. Daugird AJ, Crowell K, Saseen J Clinical inquiries. Do statins cause myopathy?. J Fam Pract 2003, 52:973-977.
20. Karim A, Abeyrantne A, Siebert F, Hetman L, Teshima K, Kondo T Tak-475, a squalene synthase inhibitor: mass balance and excretion study. Clin Pharmacol Ther 2007, 91:S114. Suppl 1 (abstract).
21. Piper E, Price G, Munsaka M, Karim A Tak-475, a squalene synthase inhibitor, coadministered with atorvastatin: a pharmacokinetic study. Clin Pharmacol Ther 2007, 91:S37. Suppl 1 (abstract).
22. Piper E, Price G, Chen Y Tak-475. a squalene synthase inhibitor improves lipid profle in hyperlipidemic subjects. Circulation 2006, 114:II-288. Suppl 18 (abstract).
23. Perez A, Kupfer S, Chen Y Addition of Tak-475 to atorvastatin provides incremental lipid benefits. Circulation 2006, 114:II-113. (Suppl 18) (abstract 675).
24. Davidson MH, Maki KC, Zavoral JH, Yu S, Popovici C, Price GD Lapaquistat acetate, a novel squalene synthase inhibitor, co-administered with atorvastatin reduces plasma lipids and C-reactive protein levels in subjects with primary hypercholesterolemia. Presented at American Heart Association conference 2007, 114:II-113. Orlando, FL, November 4-7, (abstract 193).
25. Bays H, Ballantyne C Adiposopathy: why do adiposity and obesity cause metabolic disease?. Future Lipidol 2006, 1:389-420.
26. Bays H, Blonde L, Rosenson R Adiposopathy: How do diet, exercise, weight loss and drug therapies improve metabolic disease?. Expert Rev Cardiovasc Ther 2006, 4:871-895.
27. Bays H, Dujovne CA Adiposopathy is a more rational treatment target for metabolic disease than obesity alone. Curr Atheroscler Rep 2006, 8:144-156.
28. Wetterau JR, Gregg RE, Harrity TW An MTP inhibitor that normalizes atherogenic lipoprotein levels in WHHL rabbits. Science 1998, 282:751-754.
29. Berriot-Varoqueaux N, Aggerbeck LP, Samson-Bouma M The role of the microsomal triglygeride transfer protein in abetalipoproteinemia. Annu Rev Nutr 2000, 20:663-697.
30. Avigan MI, Ishak KG, Gregg RE Morphologic features of the liver in abetalipoproteinemia. Hepatology 1984, 4:1223-1226.
31. Partin JS, Partin JC, Schubert WK Liver ultrastructure in abetalipoproteinemia: evolution of micronodular cirrhosis. Gastroenterology 1974, 67:107-118.
32. Hooper AJ, Robertson K, Barrett PH Postprandial lipoprotein metabolism in familial hypobetalipoproteinemia. J Clin Endocrinol Metab 2007, 92:1474-1478.
33. Sen D, Dagdelen S, Erbas T Hepatosteatosis with hypobetalipoproteinemia. J Natl Med Assoc 2007, 99:284-286.
34. Aegerion Pharmaceuticals, Inc. Common stock registration statement. Amendment no. 3 to Form S-1. Washington, DC: U.S. Securities Exchange Commission, 2007.
35. Cuchel M, Bloedon LT, Szapary PO Inhibition of microsomal triglyceride transfer protein in familial hypercholesterolemia. N Engl J Med 2007, 356:148-156.
36. Samaha FF, Mckenney J, Bloedon LT, Sasiela WJ, Rader DJ Efficacy and safety of the MTP-inhibitor AEGR-733, as monotherapy and in combination with ezetimibe. Presented at Drugs Affecting Lipid Metabolism Conference 2007, 92:1474-1478. New York, October 4-7, (abstract 330).
37. Samaha FF, Mckenney J, Bloedon LT, Sasiela WJ, Rader DJ MTP-inhibitor, AEGR-733, reduces body weight in patients with hypercholesterolemia. Presented at Drugs Affecting Lipid Metabolism Conference 2007, 92:1474-1478. New York, October 4-7, (abstract 345).
38. Jason TL, Koropatnick J, Berg RW Toxicology of antisense therapeutics. Toxicol Appl Pharmacol 2004, 201:66-83.
39. Vitravene Study Group The Safety Of intravitreous fomivirsen for treatment of cytomegalovirus retinitis in patients with AIDS. Am J Ophthalmol 2002, 133:484-498.
40. Grillone LR, Lanz R Fomivirsen. Drugs Today (Barc) 2001, 37:245-255.
41. Isis Pharmaceuticals Product Pipeline. Accessed June 11, 2007. http://www.isispharm.com/productpipeline.html#301012.
42. Burnett JR Drug evaluation: Isis-301012, an antisense oligonucleotide for the treatment of hypercholesterolemia. Curr Opin Mol Ther 2006, 8:461-467.
43. Kastelein, et al, Kastelein JJ, Wedel MK, Baker BF, Potent reduction of apolipoprotein B and low-density lipoprotein cholesterol by short-term administration of an antisense inhibitor of apolipoprotein B. Circulation 114, 1729-1735 .
44. Brookes L Antisense drug Isis 301012 lowers LDL cholesterol alone and in combination with statins. Medscape Cardiology 2007, June 12.
45. Casey PJ Biochemistry of protein prenylation. J Lipid Res 1992, 33:1731-1740.
46. Craig S: Rhabdomyolysis. . Last accessed May 21, 2007. http://www.emedicine.com/emerg/topic508.htm.
47. E. Muscal Rhabdomyolysis. . Last accessed May 21, 2007. http://www.emedicine.com/ped/topic2003.htm.
48. Sauret JM, Marinides G, Wang GK Rhabdomyolysis. Am Fam Physician 2002, 65:907-912.
49. Bays HE. Ezetimibe. Expert Opin Investig Drugs 2002, 11:1587-1604.
50. Bays H, Ballantyne C. Adiposopathy: why do adiposity and obesity cause metabolic disease?. Future Lipidol 2006, 1:389-420.
51. Bays H, McKenney J, Davidson M Torcetrapib/atorvastatin combination therapy. Expert Rev Cardiovasc Ther 2005, 3:789-820.